Intl Fcstone Inc. Purchases Shares of 9,459 Becton, Dickinson and Company (BDX)

Intl Fcstone Inc. acquired a new position in shares of Becton, Dickinson and Company (NYSE:BDX) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 9,459 shares of the medical instruments supplier’s stock, valued at approximately $1,846,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Westwood Holdings Group Inc. raised its position in shares of Becton, Dickinson and by 24.2% during the second quarter. Westwood Holdings Group Inc. now owns 1,056,487 shares of the medical instruments supplier’s stock worth $206,136,000 after purchasing an additional 205,721 shares during the period. Colony Group LLC grew its stake in shares of Becton, Dickinson and by 2.1% during the 2nd quarter. Colony Group LLC now owns 11,889 shares of the medical instruments supplier’s stock worth $2,320,000 after acquiring an additional 239 shares during the period. State Street Corp grew its stake in shares of Becton, Dickinson and by 3.5% during the 2nd quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock worth $2,003,834,000 after acquiring an additional 342,873 shares during the period. Peapack Gladstone Financial Corp boosted its stake in Becton, Dickinson and by 1.3% in the 2nd quarter. Peapack Gladstone Financial Corp now owns 36,472 shares of the medical instruments supplier’s stock worth $7,116,000 after purchasing an additional 453 shares during the period. Finally, Janney Montgomery Scott LLC boosted its stake in Becton, Dickinson and by 35.3% in the 2nd quarter. Janney Montgomery Scott LLC now owns 43,293 shares of the medical instruments supplier’s stock worth $8,447,000 after purchasing an additional 11,300 shares during the period. 86.01% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Intl Fcstone Inc. Purchases Shares of 9,459 Becton, Dickinson and Company (BDX)” was first published by Week Herald and is owned by of Week Herald. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://weekherald.com/2017/11/14/intl-fcstone-inc-invests-1-85-million-in-becton-dickinson-and-company-bdx.html.

Shares of Becton, Dickinson and Company (NYSE:BDX) traded up $0.77 on Tuesday, hitting $220.00. 867,100 shares of the company’s stock were exchanged, compared to its average volume of 1,334,423. Becton, Dickinson and Company has a 52 week low of $161.29 and a 52 week high of $225.23. The company has a debt-to-equity ratio of 1.48, a quick ratio of 5.01 and a current ratio of 5.56. The firm has a market cap of $50,180.00, a price-to-earnings ratio of 23.10, a PEG ratio of 1.72 and a beta of 1.04.

Becton, Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.37 by $0.03. Becton, Dickinson and had a net margin of 8.52% and a return on equity of 22.51%. The company had revenue of $3.17 billion during the quarter, compared to analyst estimates of $3.14 billion. During the same period last year, the business earned $2.12 EPS. The firm’s revenue for the quarter was down 2.0% compared to the same quarter last year. equities research analysts anticipate that Becton, Dickinson and Company will post 10.63 EPS for the current year.

Several research firms recently issued reports on BDX. Stifel Nicolaus restated a “buy” rating and set a $245.00 price target on shares of Becton, Dickinson and in a research report on Friday, November 3rd. Morgan Stanley lifted their price objective on Becton, Dickinson and from $205.00 to $245.00 and gave the stock an “equal weight” rating in a research report on Friday, November 3rd. Royal Bank Of Canada reiterated a “sector perform” rating and set a $230.00 price objective (up previously from $210.00) on shares of Becton, Dickinson and in a research note on Friday, November 3rd. Zacks Investment Research upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $234.00 price objective for the company in a research report on Tuesday, October 31st. Finally, Wells Fargo & Company reissued a “positive” rating and set a $235.00 price target (up previously from $225.00) on shares of Becton, Dickinson and in a report on Tuesday, October 24th. They noted that the move was a valuation call. Five analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Becton, Dickinson and currently has a consensus rating of “Buy” and a consensus target price of $213.47.

In other news, insider Gary M. Cohen sold 15,512 shares of the company’s stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $203.77, for a total value of $3,160,880.24. Following the sale, the insider now owns 95,781 shares of the company’s stock, valued at approximately $19,517,294.37. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Stephen Sichak sold 11,787 shares of the stock in a transaction dated Friday, September 8th. The stock was sold at an average price of $200.46, for a total transaction of $2,362,822.02. Following the sale, the insider now directly owns 14,038 shares in the company, valued at approximately $2,814,057.48. The disclosure for this sale can be found here. Insiders have sold a total of 47,038 shares of company stock valued at $9,480,225 over the last three months. 1.40% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply